louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06933901: Impact of the Operator Performing Oocyte Retrieval on the Cumulative Live Birth Rate
Official title: Does the Operator Performing the Oocyte Retrieval Have an Impact on the Cumulative Live Birth Rate: A Monocentric Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility (IVF Patients)
Oocyte Retrieval
Lead sponsor: Istituto Clinico Humanitas
Sponsor class: OTHER
First posted: 2025-04-18
Enrollment: 19500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study sample will include all operators who performed oocyte retrievals for ART cycles at the Humanitas Fertility Center between January 2013 and December 2022, in accordance with the inclusion and exclusion criteria outlined above.

Brief summary: This is a monocentric retrospective observational study. The study investigates the impact of the operator performing the oocyte retrieval on the cumulative live birth rate (CLBR).

The objectives of the study are as follows:

* To evaluate whether the operator performing the oocyte retrieval influences the probability of pregnancy, expressed as the cumulative live birth rate (CLBR).
* To assess whether operator performance improves with increased experience.

To address the study objectives, data will be collected using a specific internal web-based database. All oocyte retrieval procedures performed at the Humanitas Fertility Center from January 2013 to December 2022 will be included in the evaluation. Outcomes will be expressed in terms of CLBR.


Eligibility criteria: Inclusion Criteria:

The study database will include patients who underwent oocyte retrieval procedures with the intention of achieving pregnancy at the Humanitas Fertility Center between January 2013 and December 2022, including repeated ART cycles.

Operator experience will be assessed based on the number of previously performed oocyte retrieval procedures. All operators who performed at least 50 procedures, either at IRCCS - Humanitas Research Hospital or at another institution, will be included in the study.

Exclusion Criteria:

Patients who underwent preimplantation genetic testing (PGT) cycles, as well as those who underwent cryopreservation for oncological or elective purposes, will be excluded from the study.

Operators who performed fewer than 50 oocyte retrievals, either at IRCCS - Humanitas Research Hospital or at another institution, will be excluded. Additionally, the first 50 procedures performed by each operator will not be included in the dataset.

Primary outcomes:
measure: Cumulative live birth rate
timeFrame: January 2013 - December 2022
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00238901: Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation
Official title: Efficacy and Safety of Basiliximab in HCV+ Patients Undergoing Liver Transplantation, as Compared With Steroids, Both Given in Combination With Cyclosporine and Mycophenolate Mofetil (MMF)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Liver Transplant
Keywords: Liver transplant, HCV+, steroid free
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-10-14
Enrollment: 194
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The natural history of HCV infection in liver transplant recipients may be accelerated when compared to that in patients with normal immune systems.

The objective of this trial is to assess the efficacy and safety of basiliximab, in combination with cyclosporin and MMF on the success rate of liver transplants for HCV related cirrhosis, in comparison with standard steroid treatment.


Eligibility criteria: Inclusion Criteria Patients undergoing first cadaver liver transplant Patients receiving an AB0 identical or compatible graft HCV+ patients (serology test within the last 12 months)

Exclusion Criteria Antiretroviral prophylactic treatment post-transplant Serological markers positive for Hepatitis B surface Antigen and Human Immunodeficiency Virus Recipients of a split liver transplant Other protocol-defined inclusion/exclusion criteria applied

Primary outcomes:
measure: 12-month cumulative incidence of post-surgical graft loss and death
Secondary outcomes:
measure: hepatitis C recurrence (see definition 3.5.2) at 6 and 12 months after transplant surgery.
measure: treated and biopsy proven acute rejection at 6 and 12 months after transplant surgery.
measure: graft survival and patient survival after treatment with either Simulect or steroids at 6 and 12 months.
measure: viral load (HCV-RNA) after treatment with Simulect or steroids at Baseline, Month 1 and 3 post transplantation.
Other outcomes:
Locations:
Study officials:
affiliation: Novartis
name: Novartis
role: STUDY_DIRECTOR
References:
Clinical trial NCT03981601: Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Lovastatin in the Preservation of the Tooth Socket
Official title: the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) With Lovastatin in the Preservation of the Tooth Socket
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Bone Loss
Lead sponsor: Islamic Azad University, Sanandaj
Sponsor class: OTHER
First posted: 2019-06-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Twenty patients referring to periodontics department of Boroujerd Azad university of dentistry after obtaining consent to participate in the research project, which have more than 20 teeth, are over 18 years old and require socket preservation surgery to tooth extraction for the periodontal problem, caries or Fractures were selected.

Detailed description: twenty healthy patients referring to periodontics department of Boroujerd Azad university of dentistry after obtaining consent to participate in the research project, which has more than 20 teeth, are over 18 years old and require socket preservation surgery to tooth extraction for the periodontal problem, caries or Fractures were selected. moreover, divided the socket randomly to two groups(A, B)including A: bone graft with lovastatin and B: bone graft alone, after 3 months with trephine will collect the samples. following the histomorphometric analysis.

Eligibility criteria: Inclusion Criteria:

1. at least 18 years old
2. tooth fracture, root caries
3. Patients are volunteered for placement of the implant

Exclusion Criteria:

1. systemic diseases
2. Pregnancy and breastfeeding
3. malignancy, radiation therapy,
4. history of periodontal surgery during the six months ago.
5. medicine(phosphonates, antibiotic,...)

Primary outcomes:
measure: Socket preservation with Lovastatin as evaluated by the amount of bone formation volume
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Amirhossein Farahmand
Study officials:
References:
Clinical trial NCT03810001: Mechanical Stimulation Improve the Fertilization in ICSI Cycle
Official title: Use of Mechanical Stimulation to Active Oocytes Can Improve the Fertilization in Intracytoplasmic Sperm Injection Cycle
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fertilization
Keywords: oocyte activation
intracytoplasmic sperm injection(ICSI)
mechanical stimulation
2PN rate
Lead sponsor: Tang-Du Hospital
Sponsor class: OTHER
First posted: 2019-01-18
Enrollment: 500
Sex: FEMALE
Minimum age (years): 22
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Most fertilization failures after ICSI are caused by failure of oocyte activation defects. But, to date, there is no effective method to overcome this obstacle. To investigate the effect of mechanical stimulation on fertilization failures, investigators plan to recruit women undergoing ICSI treatment cycles. The retrieved sibling oocytes from the patients were randomly divided into two groups. The control group conducted the standard ICSI procedure, while the experimental group conducted the modified ICSI procedure.Consequently, the fertilization rate, 2PN (two pronuclei) rate, 1PN rate, oocyte degradation rate,and exploitable embryos on D3 were recorded to evaluate ICSI cycle outcomes.

Detailed description: Normal fertilization is the critical for the success of ICSI. To investigate the effect of mechanical stimulation on fertilization, investigators plan to recruit women undergoing ICSI treatment cycles. Exclusion criteria: Patients older than 40 years, the maturation oocytes less than 6. The retrieved sibling oocytes from the patient were randomly divided into two groups. The control group conducted the standard ICSI procedure, while the experimental group conducted the modified ICSI procedure. The modified ICSI procedure involved a micromanipulation mechanical stimulation between insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon from the needle to the ooplasm, without additional reagents treatment. Consequently, the fertilization rate, 2PN rate, 1PN rate, oocyte degradation rate, and exploitable embryos on D3 were recorded. The investigators aim to evaluate whether the mechanical stimulation can be used to improve the normal fertilization and embryo quality in ICSI cycles.

Eligibility criteria: Inclusion Criteria:

* oocytes number ≥ 8;
* women undergoing intracytoplasmic sperm injection cycle.

Exclusion Criteria:

* maturation oocytes number less than 6.

Primary outcomes:
measure: Normal fertilization rate
timeFrame: 6 months
Secondary outcomes:
measure: Feasibility and Efficacy of Mechanical Stimulation
timeFrame: 6 months
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Tangdu Hospital
state: Shaanxi
Study officials:
affiliation: Reproductive Medicine Center, Tangdu Hospital
name: li bo
role: STUDY_CHAIR
References:
Clinical trial NCT01772901: Brief Influenza Vaccine Education to Pregnant Women
Official title: A Randomized Controlled Trial of a Brief Educational Intervention to Increase Uptake of Influenza Vaccine Among Pregnant Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Influenza
Infectious Disease
Pregnancy
Keywords: influenza
influenza vaccines
infectious disease
pregnancy
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Food and Health Bureau, Hong Kong
First posted: 2013-01-21
Enrollment: 321
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators will conduct a brief educational intervention to pregnant women who have not yet received the influenza vaccine in this pregnancy to improve the uptake of seasonal influenza vaccine.


Eligibility criteria: Inclusion Criteria:

* singleton pregnancy
* 18 years of age or older
* in at least the second trimester of pregnancy
* Cantonese speaking
* Hong Kong resident
* no serious medical or obstetrical complications
* have not yet received the influenza vaccine in this pregnancy
* staying in Hong Kong for at least two weeks after delivery.

Exclusion Criteria:

* not entitled to health benefits in Hong Kong (NEP)

Primary outcomes:
measure: The proportion of influenza vaccination
timeFrame: 2 weeks postpartum
Secondary outcomes:
measure: The influenza and influenza vaccine knowledge of participants
timeFrame: 2 weeks postpartum
measure: the proportion of participants initiating discussion about influenza vaccine with their health care provider
timeFrame: 2 weeks postpartum
measure: the proportion of participants seeking out influenza vaccine
timeFrame: 2 weeks postpartum
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Kwong Wah Hospital
city: Hong Kong
country: Hong Kong
facility: Pamela Youde Nethersole Eastern Hospital
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital
city: Hong Kong
country: Hong Kong
facility: Tsan Yuk Hospital
Study officials:
affiliation: The University of Hong Kong
name: Marie TARRANT, PhD, MPH, RN
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wong VWY, Fong DYT, Lok KYW, Wong JYH, Sing C, Choi AY, Yuen CYS, Tarrant M. Brief education to promote maternal influenza vaccine uptake: A randomized controlled trial. Vaccine. 2016 Oct 17;34(44):5243-5250. doi: 10.1016/j.vaccine.2016.09.019. Epub 2016 Sep 22.
citation: Wong VW, Fong DY, Tarrant M. Brief education to increase uptake of influenza vaccine among pregnant women: a study protocol for a randomized controlled trial. BMC Pregnancy Childbirth. 2014 Jan 14;14:19. doi: 10.1186/1471-2393-14-19.
Clinical trial NCT03962101: Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
Official title: A Multicenter, Open-label, Uncontrolled Clinical Trial to Confirm the Tolerability of OPC-61815 in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Congestive Heart Failure
Lead sponsor: Otsuka Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2019-05-23
Enrollment: 45
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To confirm the tolerability of intravenous administration of OPC-61815 at 8 or 16 mg once daily for a maximum of 5 days to CHF patients with volume overload despite having received diuretics (injection) other than vasopressin antagonists and who have difficulty with or are incapable of oral intake.


Eligibility criteria: Inclusion Criteria:

* Patients receiving loop diuretic injection at a dose equivalent to furosemide 20 mg/day or higher
* CHF patients in whom lower limb edema, pulmonary congestion, and/or jugular venous distension due to volume overload is present
* Patients who are judged by the investigator or subinvestigator to have difficulty or be incapable of oral intake, including patients who are judged by the investigator or subinvestigator to require nothing by mouth(NPO) management
* Patients who are currently hospitalized or who are capable of being hospitalized from the time of informed consent until the end of the treatment period
* Patients who are capable of giving informed consent

Exclusion Criteria:

* Patients who are on a ventricular assist device
* Patients who have difficulty with spontaneous respiration or who have been on tracheal intubation under sedative therapy
* Patients with severe disturbed consciousness (ie, coma or stupor)

Primary outcomes:
measure: Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
timeFrame: From the start of IMP administration (Day 1) up to 15 days
Secondary outcomes:
measure: Change From Baseline in Body Weight
timeFrame: Baseline, Day after final IMP administration
measure: Improvement Rate for Lower Limb Edema
timeFrame: Baseline, Day after final IMP administration
measure: Improvement Rate for Pulmonary Congestion
timeFrame: Baseline, Day after final IMP administration
Other outcomes:
Locations:
city: Gifu
country: Japan
facility: Gifu Prefectural General Medical Center
Study officials:
affiliation: Otsuka Pharmaceutical Co., Ltd.
name: Takehisa Matsumaru
role: STUDY_DIRECTOR
References:
Clinical trial NCT00638001: Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Haemophilia A
Haemophilia B
Keywords: patients with haemophilia A moderate or severe
patients with haemophilia B moderate or severe
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2008-03-18
Enrollment: 70
Sex: MALE
Minimum age (years): 13
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study intend to evaluate the effectiveness of functional orthoses (including custom-made insoles and shoes) for preventing and controlling repetitive haemarthrosis in patients suffering of haemophilic ankle arthropathy, as well as the orthoses' impact on foot health-related quality of life.


Eligibility criteria: Inclusion Criteria:

* haemophilia A or B, aged more than 13 years

Exclusion Criteria:

* impossibility to walk on a treadmill
* recent joint haemarthrosis or muscle haematoma

Primary outcomes:
measure: Gait analysis, foot pressure measurement, specific joint score
timeFrame: To, T1 (3months) and T2 (6months)
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: cliniques Universitaires Saint Luc
Study officials:
References:
Clinical trial NCT04938401: Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection
Official title: Construction and Application of a Risk Prediction Model Forepistaxis After Endoscopic Transsphenoidal Pituitary Tumor Resection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pituitary Tumor
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
Collaborators: name: Sir Run Run Shaw Hospital
name: Zhejiang University
name: Zhejiang Provincial People's Hospital
First posted: 2021-06-24
Enrollment: 1
Sex: ALL
Minimum age (years): 14
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients after transnasal sphenoidal resection of pituitary tumor

Brief summary: (1) Objective to establish an evaluation system for predicting the risk of epistaxis after endoscopic transsphenoidal pituitary surgery（ 2) Objective to determine the risk factors of epistaxis after endoscopic transsphenoidal pituitary adenoma surgery. Referring to domestic and foreign literature, combined with experts' opinions, the related risk factors that may cause postoperative nosebleed of pituitary adenoma are: 22 patients and surgical factors. 3) Objective to establish a risk prediction model of epistaxis after endoscopic transsphenoidal pituitary tumor resection. According to the occurrence of epistaxis, the patients in the modeling group were divided into epistaxis group and non epistaxis group. The risk factors of epistaxis were taken as the independent variable, and the occurrence of epistaxis was taken as the dependent variable. The variables with statistical significance in univariate analysis were included in the multivariate logistic regression model, and the risk prediction model of epistaxis after pituitary tumor resection was established by back LR method.(4) Objective to verify the risk prediction model of endoscopic transsphenoidal pituitary adenoma epistaxis. The validation model is used to validate the prediction model, and the Hosmer-Lemeshow degree is used to match the model. The area under the receiver operating characteristic curve (ROC) was used to evaluate the validity of the model.(5) Application of risk prediction model.


Eligibility criteria: Inclusion Criteria:

Those who met the diagnostic criteria of pituitary tumor and received transsphenoidal endoscopic surgery during hospitalization; Patients with informed consent; Age ≥ 14 years old.

Exclusion Criteria:

quitters; patients with incomplete clinical data;

Primary outcomes:
measure: Incidence of epistaxis
timeFrame: up to 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Second Affiliated Hospital, School of Medicine, Zhejiang University
name: YIing Wang
role: STUDY_CHAIR
References:
Clinical trial NCT03316001: Mesenteric Panniculitis : Review of Consecutive Abdominal MDCT Examinations With a Matched-pair Analysis
Official title: Mesenteric Panniculitis : Review of Consecutive Abdominal MDCT Examinations With a Matched-pair Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mesenteric Panniculitis
Lead sponsor: CHU de Reims
Sponsor class: OTHER
First posted: 2017-10-20
Enrollment: 288
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed

Brief summary: Mesenteric panniculitis is a benign inflammatory condition that involves the adipose tissue of the intestinal mesentery. Clinical manifestations are uncommon, non specific and atypical. Mesenteric panniculitis is thus most often an incidental finding during an investigation for other reason, mostly on computed tomography scans. The rate of malignancy in patients with mesenteric panniculitis, especially urogenital and gastrointestinal adenocarcinomas or lymphomas, has been reported to be as high, thus suggesting that there may be a relationship between mesenteric panniculitis and progression of an underlying malignancy or the risk of a future malignancy.

Detailed description: The aim was:

to estimate the prevalence of mesenteric panniculitis. to study relationship between mesenteric panniculitis and malignancy. to investigate the 5-year outcome of patients with mesenteric panniculitis for the development of malignancy.

Eligibility criteria: inclusion criteria:

* Patients with a CT scan from January to August 2008
* Patients with diagnosis of mesenteric panniculitis on CT scan

exclusion criteria:

* Patients with disease that may cause mesenteric infiltration

Primary outcomes:
measure: mesenteric panniculitis
timeFrame: Day 0
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Protin-Catteau L, Thiefin G, Barbe C, Jolly D, Soyer P, Hoeffel C. Mesenteric panniculitis: review of consecutive abdominal MDCT examinations with a matched-pair analysis. Acta Radiol. 2016 Dec;57(12):1438-1444. doi: 10.1177/0284185116629829. Epub 2016 Jul 19.